Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in Unresectable Intrahepatic Cholangiocarcinoma
NCT03801499Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen University. Planned start Sep 2018; status: withdrawn.
02
Drugs
lenvatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03801499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801499.